TrivarX announces major R&D milestone

TrivarX (ASX:TRI) has completed an R&D program, resulting in a significant enhancement of their MEB-001 algorithm. This new development enables the screening of current Major Depressive Episode (cMDE) using a single lead ECG, expanding potential market applications.

TrivarX's strategic vision and future prospects

TrivarX has successfully advanced its MEB-001 algorithm, allowing for the screening of current Major Depressive Episode using a single lead ECG. This achievement demonstrates an 87% sensitivity and 67% specificity, opening new markets beyond sleep centers. The company has filed a provisional patent in the US and is preparing for further trials that could lead to FDA clearance. This development aligns with TrivarX's strategy to leverage AI in mental health assessments, aiming to expand their market reach and maintain a competitive edge.

Executive insights on algorithm breakthrough

The development of the MEB-001 algorithm marks a significant milestone for TrivarX, as it positions us to expand our reach beyond traditional sleep centers into cardiology monitoring, sports and performance, military, treatment monitoring, and consumer wearables. This innovation supports our goal of becoming a leader in AI-based mental health assessments and opens up new commercial opportunities. The upcoming pivotal trials are expected to pave the way for FDA clearance, potentially enhancing our market presence and endorsement of our technology.